IGC Pharma
25 hedge funds and large institutions have $5.08M invested in IGC Pharma in 2020 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 4 closing their positions.
132% more capital invested
Capital invested by funds: $2.19M → $5.08M (+$2.89M)
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
4% more funds holding
Funds holding: 24 → 25 (+1)
2.51% more ownership
Funds ownership: 5.1% → 7.62% (+2.5%)
22% less call options, than puts
Call options by funds: $377K | Put options by funds: $485K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.3M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$360K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$189K |
| 4 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
+$41.7K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$38K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$115K |
| 2 |
CFA
Carroll Financial Associates
Charlotte,
North Carolina
|
-$103K |
| 3 |
SFS
Sowell Financial Services
North Little Rock,
Arkansas
|
-$37.2K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$31.8K |
| 5 |
PIA
Powell Investment Advisors
Miami,
Florida
|
-$26K |
IGC Hedge Fund Activity: Q4 2020 in Review
25 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q4 2020, worth a combined $5.08M — up 132% from $2.19M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new IGC positions and 4 closed out — a net gain of 1 holder — while 8 added to existing stakes and 5 trimmed.
The largest buyer was BlackRock, adding an estimated $1.3M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $115K sold.
- 25 institutional investors held IGC Pharma (IGC) as of Q4 2020, up from 24 in Q3 2020.
- Funds reported $5.08M of IGC Pharma stock for Q4 2020, up 132% quarter-over-quarter.
- 5 funds opened new IGC Pharma positions in Q4 2020 and 4 closed out, a net change of +1 holder.
- The largest IGC Pharma buyer in Q4 2020 was BlackRock, an estimated $1.3M added.
- The largest IGC Pharma seller in Q4 2020 was Renaissance Technologies, an estimated $115K sold.
Based on aggregated 13F filings for Q4 2020.